Patents by Inventor Todd Macklin

Todd Macklin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted pyrido[3,4-b]pyrazines as GPR6 modulators
    Patent number: 10738046
    Abstract: The present invention provides compounds of formula I: which are useful as modulators of GPR6, pharmaceutical compositions thereof, methods for treatment of conditions associated with GPR6, processes for making the compounds and intermediates thereof.
    Type: Grant
    Filed: August 7, 2018
    Date of Patent: August 11, 2020
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Jason W. Brown, Stephen Hitchcock, Maria Hopkins, Shota Kikuchi, Holger Monenschein, Holly Reichard, Kristin Schleicher, Huikai Sun, Todd Macklin
  • Tetrahydropyridopyrazines as modulators of GPR6
    Patent number: 10597392
    Abstract: The present invention provides compounds of formula I: which are useful as modulators of GPR6, pharmaceutical compositions thereof, methods for treatment of conditions associated with GPR6, processes for making the compounds and intermediates thereof.
    Type: Grant
    Filed: November 30, 2018
    Date of Patent: March 24, 2020
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Stephen Hitchcock, Maria Hopkins, Shota Kikuchi, Holger Monenschein, Holly Reichard, Huikai Sun, Todd Macklin
  • Tetrahydropyridopyrazine modulators of GPR6
    Patent number: 10406157
    Abstract: Disclosed is a compound of Formula 1, and a pharmaceutically acceptable salt thereof. This disclosure also relates to materials and methods for preparing the compound of Formula 1, to pharmaceutical compositions which contain it, and to its use for treating diseases, disorders, and conditions associated with GPR6.
    Type: Grant
    Filed: June 15, 2018
    Date of Patent: September 10, 2019
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Jason W. Brown, Stephen Hitchcock, Maria Hopkins, Shota Kikuchi, Holger Monenschein, Holly Reichard, Kristin Schleicher, Huikai Sun, Todd Macklin
  • 5-HT3 receptor antagonists
    Patent number: 10407443
    Abstract: The present invention provides 5-HT3 receptor antagonists of Formula (I): which are useful for the treatment of diseases treatable by inhibition of 5-HT3 receptor such as emesis, pain, drug addiction, neurodegenerative and psychiatric disorders, and GI disorders. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Grant
    Filed: July 23, 2018
    Date of Patent: September 10, 2019
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Stephen Hitchcock, Holger Monenschein, Holly Reichard, Huikai Sun, Todd Macklin, Maria Hopkins, Shota Kikuchi
  • TETRAHYDROPYRIDOPYRAZINES MODULATORS OF GPR6
    Publication number: 20190263801
    Abstract: The present invention provides compounds of formula I: which are useful as modulators of GPR6, pharmaceutical compositions thereof, methods for treatment of conditions associated with GPR6, processes for making the compounds and intermediates thereof.
    Type: Application
    Filed: November 30, 2018
    Publication date: August 29, 2019
    Inventors: Stephen Hitchcock, Maria Hopkins, Shota Kikuchi, Holger Monenschein, Holly Reichard, Huikai Sun, Todd Macklin
  • Tetrahydropyridopyrazines as modulators of GPR6
    Patent number: 10179783
    Abstract: The present invention provides compounds of formula I: which are useful as modulators of GPR6, pharmaceutical compositions thereof, methods for treatment of conditions associated with GPR6, processes for making the compounds and intermediates thereof.
    Type: Grant
    Filed: February 13, 2015
    Date of Patent: January 15, 2019
    Assignee: Taketa Pharmaceutical Company Limited
    Inventors: Stephen Hitchcock, Maria Hopkins, Shota Kikuchi, Holger Monenschein, Holly Reichard, Huikai Sun, Todd Macklin
  • TETRAHYDROPYRIDOPYRAZINE MODULATORS OF GPR6
    Publication number: 20180360831
    Abstract: Disclosed is a compound of Formula 1, and a pharmaceutically acceptable salt thereof. This disclosure also relates to materials and methods for preparing the compound of Formula 1, to pharmaceutical compositions which contain it, and to its use for treating diseases, disorders, and conditions associated with GPR6.
    Type: Application
    Filed: June 15, 2018
    Publication date: December 20, 2018
    Inventors: Jason W. Brown, Stephen Hitchcock, Maria Hopkins, Shota Kikuchi, Holger Monenschein, Holly Reichard, Kristin Schleicher, Huikai Sun, Todd Macklin
  • SUBSTITUTED PYRIDO[3,4-b]PYRAZINES AS GPR6 MODULATORS
    Publication number: 20180346464
    Abstract: The present invention provides compounds of formula I: which are useful as modulators of GPR6, pharmaceutical compositions thereof, methods for treatment of conditions associated with GPR6, processes for making the compounds and intermediates thereof.
    Type: Application
    Filed: August 7, 2018
    Publication date: December 6, 2018
    Inventors: Jason W. Brown, Stephen Hitchcock, Maria Hopkins, Shota Kikuchi, Holger Monenschein, Holly Reichard, Kristin Schleicher, Huikai Sun, Todd Macklin
  • 5-HT3 RECEPTOR ANTAGONISTS
    Publication number: 20180327421
    Abstract: The present invention provides 5-HT3 receptor antagonists of Formula (I): which are useful for the treatment of diseases treatable by inhibition of 5-HT3 receptor such as emesis, pain, drug addiction, neurodegenerative and psychiatric disorders, and GI disorders. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Application
    Filed: July 23, 2018
    Publication date: November 15, 2018
    Inventors: Stephen Hitchcock, Holger Monenschein, Holly Reichard, Huikai Sun, Todd Macklin, Maria Hopkins, Shota Kikuchi
  • 5-HT3 receptor antagonists
    Patent number: 10125145
    Abstract: The present invention provides 5-HT3 receptor antagonists of Formula (I): which are useful for the treatment of diseases treatable by inhibition of 5-HT3 receptor such as emesis, pain, drug addiction, neurodegenerative and psychiatric disorders, and GI disorders. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Grant
    Filed: May 18, 2017
    Date of Patent: November 13, 2018
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Stephen Hitchcock, Holger Monenschein, Holly Reichard, Huikai Sun, Shota Kikuchi, Todd Macklin, Maria Hopkins
  • Substituted pyrido[3,4-b]pyrazines as GPR6 modulators
    Patent number: 10077266
    Abstract: The present invention provides compounds of formula I: which are useful as modulators of GPR6, pharmaceutical compositions thereof, methods for treatment of conditions associated with GPR6, processes for making the compounds and intermediates thereof.
    Type: Grant
    Filed: June 13, 2017
    Date of Patent: September 18, 2018
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Jason W. Brown, Stephen Hitchcock, Maria Hopkins, Shota Kikuchi, Holger Monenschein, Holly Reichard, Kristin Schleicher, Huikai Sun, Todd Macklin
  • 5HT3 RECEPTOR ANTAGONISTS
    Publication number: 20180072758
    Abstract: The present invention provides compounds of the formula: that are 5-HT3 receptor antagonists and are therefore useful for the treatment of diseases treatable by inhibition of 5-HT3 receptor such as emesis, pain, drug addiction, neurodegenerative and psychiatric disorders, and GI disorders. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Application
    Filed: May 31, 2017
    Publication date: March 15, 2018
    Inventors: Stephen Hitchcock, Holger Monenschein, Holly Reichard, Huikai Sun, Shota Kikuchi, Todd Macklin, Maria Hopkins
  • TETRAHYDROPYRIDOPYRAZINES MODULATORS OF GPR6
    Publication number: 20170283414
    Abstract: The present invention provides compounds of formula I: which are useful as modulators of GPR6, pharmaceutical compositions thereof, methods for treatment of conditions associated with GPR6, processes for making the compounds and intermediates thereof.
    Type: Application
    Filed: June 13, 2017
    Publication date: October 5, 2017
    Inventors: Jason W. Brown, Stephen Hitchcock, Maria Hopkins, Shota Kikuchi, Holger Monenschein, Holly Reichard, Kristin Schleicher, Huikai Sun, Todd Macklin
  • Quinoxaline derivatives as GPR6 modulators
    Patent number: 9770452
    Abstract: The present invention provides compounds of Formula (I): that are GPR6 modulators and are therefore useful for the treatment of diseases treatable by modulation of GPR6, in particular treating Parkinson disease, levodopa induced dyskinesias, Huntington's disease, other dyskinesias, akinesias, and motor disorders involving dysfunction of the striatum, schizophrenia and drug addiction. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Grant
    Filed: October 25, 2016
    Date of Patent: September 26, 2017
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Stephen Hitchcock, Holger Monenschein, Holly Reichard, Huikai Sun, Shota Kikuchi, Todd Macklin, Maria Hopkins
  • 5-HT3 RECEPTOR ANTAGONISTS
    Publication number: 20170260201
    Abstract: The present invention provides 5-HT3 receptor antagonists of Formula (I): which are useful for the treatment of diseases treatable by inhibition of 5-HT3 receptor such as emesis, pain, drug addiction, neurodegenerative and psychiatric disorders, and GI disorders. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Application
    Filed: May 18, 2017
    Publication date: September 14, 2017
    Inventors: Stephen Hitchcock, Holger Monenschein, Holly Reichard, Huikai Sun, Shota Kikuchi, Todd Macklin, Maria Hopkins
  • Substituted pyrido[3,4-b]pyrazines as GPR6 modulators
    Patent number: 9708313
    Abstract: This present invention provides compounds of formula II: which are useful as modulators of GPR6, pharmaceutical compositions thereof, methods for treatment of conditions associated with GPR6, processes for making the compounds and intermediates thereof.
    Type: Grant
    Filed: October 14, 2015
    Date of Patent: July 18, 2017
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Jason W. Brown, Stephen Hitchcock, Maria Hopkins, Shota Kikuchi, Holger Monenschein, Holly Reichard, Kristin Schleicher, Huikai Sun, Todd Macklin
  • 5-HT3 receptor antagonists
    Patent number: 9695195
    Abstract: The present invention provides compounds of the formula: that are 5HT3 receptor antagonists and are therefore useful for the treatment of diseases treatable by inhibition of 5HT3 receptor such as emesis, pain, drug addiction, neurodegenerative and psychiatric disorders, and GI disorders. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Grant
    Filed: March 8, 2016
    Date of Patent: July 4, 2017
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Stephen Hitchcock, Holger Monenschein, Holly Reichard, Huikai Sun, Shota Kikuchi, Todd Macklin, Maria Hopkins
  • TETRAHYDROPYRIDOPYRAZINES MODULATORS OF GPR6
    Publication number: 20170174677
    Abstract: The present invention provides compounds of formula I: which are useful as modulators of GPR6, pharmaceutical compositions thereof, methods for treatment of conditions associated with GPR6, processes for making the compounds and intermediates thereof.
    Type: Application
    Filed: February 13, 2015
    Publication date: June 22, 2017
    Inventors: Stephen Hitchcock, Maria Hopkins, Shota Kikuchi, Holger Monenschein, Holly Reichard, Huikai Sun, Todd Macklin
  • 5-HT3 receptor antagonists
    Patent number: 9670229
    Abstract: The present invention provides 5-HT3 receptor antagonists of Formula (I): which are useful for the treatment of diseases treatable by inhibition of 5-HT3 receptor such as emesis, pain, drug addiction, neurodegenerative and psychiatric disorders, and GI disorders. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Grant
    Filed: May 9, 2016
    Date of Patent: June 6, 2017
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Stephen Hitchcock, Holger Monenschein, Holly Reichard, Huikai Sun, Shota Kikuchi, Todd Macklin, Maria Hopkins
  • QUINOXALINE DERIVATIVES AS GPR6 MODULATORS
    Publication number: 20170035775
    Abstract: The present invention provides compounds of Formula (I): that are GPR6 modulators and are therefore useful for the treatment of diseases treatable by modulation of GPR6, in particular treating Parkinson disease, levodopa induced dyskinesias, Huntington's disease, other dyskinesias, akinesias, and motor disorders involving dysfunction of the striatum, schizophrenia and drug addiction. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Application
    Filed: October 25, 2016
    Publication date: February 9, 2017
    Inventors: Stephen Hitchcock, Holger Monenschein, Holly Reichard, Huikai Sun, Shota Kikuchi, Todd Macklin, Maria Hopkins